^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prostate Cancer
    Drug:docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) +
    prednisone (Steroid receptor agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/11/2019
    Excerpt:
    Docetaxel Injection is a microtubule inhibitor indicated for:...Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Docetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.